Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.68
Industry P/E
--
Debt to Equity
0
ROE
-47.04 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-288.49 Mln
EBITDA
$-266.78 Mln
Net Profit
$-314.57 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Baudax Bio (BXRX)
| -54.55 | -18.03 | -58.68 | -98.69 | -98.15 | -- | -- |
|
BSE Sensex*
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2021
|
2020
|
|
|---|---|---|---|
|
Baudax Bio (BXRX)
| -99.31 | -78.30 | -85.40 |
|
S&P Small-Cap 600
| 13.89 | 25.27 | 9.57 |
|
BSE Sensex
| 18.74 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 8.30 | 36.90 | -- | 1617.91 |
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in... combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania. Read more
President, CEO & Director
Dr. Geraldine A. Henwood Ph.D.
President, CEO & Director
Dr. Geraldine A. Henwood Ph.D.
Headquarters
Malvern, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Baudax Bio Inc (BXRX) stood at $ 40 Mln as on 30-Sep-23
The share price of Baudax Bio Inc (BXRX) is $0.01 (NASDAQ) as of 02-May-2024 09:30 EDT. Baudax Bio Inc (BXRX) has given a return of -98.15% in the last 3 years.
Baudax Bio Inc (BXRX) has a market capitalisation of $ 1 Mln as on 02-May-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Baudax Bio Inc (BXRX) is 0.68 times as on 02-May-2024, a 69% discount to its peers’ median range of 2.21 times.
Since, TTM earnings of Baudax Bio Inc (BXRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Baudax Bio Inc (BXRX) and enter the required number of quantities and click on buy to purchase the shares of Baudax Bio Inc (BXRX).
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
The CEO & director of Dr. Geraldine A. Henwood Ph.D.. is Baudax Bio Inc (BXRX), and CFO & Sr. VP is Dr. Geraldine A. Henwood Ph.D..
There is no promoter pledging in Baudax Bio Inc (BXRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
4
|
| Baudax Bio Inc. (BXRX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-4974.23
|
|
Net Margin(%)
|
-2194.48
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Baudax Bio Inc (BXRX) was $-24 Mln.
